Retatrutide dosage comes up constantly in weight-loss and metabolic research discussions. Here’s the honest, plain-language version: where the trial dose numbers actually come from, what they do and don’t mean, and why this guide won’t hand you a personal dose. This article is for informational purposes only.
What Is Retatrutide?
Retatrutide is a synthetic peptide developed by Eli Lilly, and it belongs to a class of compounds called triple hormone receptor agonists, meaning it acts on three separate hormone signals at once. It’s currently in Phase 3 clinical trials and isn’t approved by the FDA or any other health authority for any use. A full explainer of what it is and how it’s thought to work is covered in our retatrutide guide.
Dosing in the Research Literature
Retatrutide’s dose numbers, unlike many earlier-stage research peptides, do come from real human clinical trials, but that’s not the same thing as an approved or personal dose. The Phase 2 obesity trial tested a handful of weekly doses, roughly 1 mg, 4 mg, 8 mg, and 12 mg, against a placebo, with participants moved up gradually through those doses over several weeks. That gradual step-up, called dose escalation, was mainly done to reduce stomach-related side effects, not because it’s a pattern meant to be copied. The Phase 3 trials have narrowed in on a smaller set of doses, with 12 mg once weekly as the highest one tested.
These numbers describe supervised clinical trial protocols, not a recommendation, and this guide won’t repeat one as if it were. They were set for specific trial populations, with medical monitoring, regular check-ins, and defined stopping rules built into the study design.
See also: The Molecule With Three Jobs
Why Trial Doses Don’t Translate to Personal Use
- The trial product isn’t what’s sold online. Trial participants received Eli Lilly’s own manufactured product under strict quality control. Material sold outside of trials has no link to that product or its testing.
- Escalation was paired with monitoring. Participants moved up in dose while being checked for side effects, and doses could be held or reduced. That safety net is part of the protocol, not an optional extra.
- Side effects were dose-dependent. Digestive side effects such as nausea, vomiting, and diarrhea became more common at higher doses, and more participants stopped treatment early at the top doses.
- Long-term safety is still being studied. Because retatrutide hasn’t completed clinical development, its long-term safety profile isn’t fully known yet.
See also: Retatrutide vs Tirzepatide, What Sets Them Apart
FAQ
What dose of retatrutide was used in clinical trials?
The Phase 2 obesity trial tested roughly 1 mg, 4 mg, 8 mg, and 12 mg weekly, escalated gradually. Phase 3 trials have tested up to 12 mg once weekly. These are supervised trial protocols, not a personal or recommended dose.
Why were doses increased gradually?
Mainly to reduce digestive side effects. Starting lower and stepping up over several weeks gave participants time to adjust, which is a common approach across this class of compounds.
Is retatrutide approved for use?
No. It’s still an investigational compound, currently in Phase 3 clinical trials, and it hasn’t been approved by the FDA or any other health authority for any use.
Research Use Disclaimer
This content is provided for Research Use Only (RUO). The compounds discussed are not drugs, dietary supplements, foods, or cosmetics, and are not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. They have not been evaluated by the FDA for safety or efficacy in humans. Any research use must be conducted by qualified professionals in a controlled laboratory environment, in accordance with all applicable institutional, local, and federal regulations.
Sources
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
- Eli Lilly and Company. What to Know About Retatrutide, official overview of its investigational status and trial results.
